---
title: "301281.SZ (301281.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/301281.SZ/news.md"
symbol: "301281.SZ"
name: "301281.SZ"
parent: "https://longbridge.com/en/quote/301281.SZ.md"
datetime: "2026-03-15T22:50:25.198Z"
locales:
  - [en](https://longbridge.com/en/quote/301281.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/301281.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/301281.SZ/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/301281.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/301281.SZ/news.md)


# 301281.SZ (301281.SZ) — Related News

### [Keyuan Pharma: Gao Chunbo resigned due to work adjustment reasons](https://longbridge.com/en/news/279007664.md)
*2026-03-13T08:25:36.000Z*
> Keyuan Pharma announced that the company's board of directors received a written resignation letter from the legal repre

### [Keyuan Pharma: Shareholders Wen Zehong and Jiang Chunmei completed a 1% reduction in holdings](https://longbridge.com/en/news/278873039.md)
*2026-03-12T11:23:35.000Z*
> Keyuan Pharma announced that shareholders holding more than 5%, Wen Zehong and his concerted actor Jiang Chunmei, have c

### [Keyuan Pharma established a leading technology company, including AI and robotics business](https://longbridge.com/en/news/278012071.md)
*2026-03-06T01:44:20.000Z*
> According to the Qichacha APP, recently, Keyuan Navigation Technology Co., Ltd. was established with a registered capita

### [Keyuan Pharma's profits fell by over 70% due to litigation, with three chairman changes in three years and failed acquisitions awaiting breakthrough](https://longbridge.com/en/news/277138017.md)
*2026-02-27T03:32:27.000Z*
> Keyuan Pharma has revised its performance forecast due to the impact of a subsidiary's lawsuit, expecting the net profit

### [Keyuan Pharma revises its 2025 performance forecast, expecting a net profit decline of 70%-80% year-on-year](https://longbridge.com/en/news/276726144.md)
*2026-02-24T11:38:53.000Z*
> Keyuan Pharma released a revised performance forecast for 2025, expecting a net profit attributable to shareholders of t

### [](https://longbridge.com/en/news/275538258.md)
*2026-02-11T02:05:25.000Z*
> The A-share vitamin sector strengthened during the trading session, Nantong Acetic Acid Chemical hit the daily limit, Ad

### [Keyuan Pharma: Shareholders plan to reduce their holdings by no more than 1% of the company's shares](https://longbridge.com/en/news/272970169.md)
*2026-01-19T12:03:29.000Z*
> On January 19th, Keyuan Pharma announced that its 5% shareholder Aito intends to reduce its holdings in the company by n

### [Keyuan Pharma plans to launch a restricted stock incentive plan in 2025](https://longbridge.com/en/news/270986994.md)
*2025-12-29T11:16:04.000Z*
> Keyuan Pharma released the draft of the 2025 Restricted Stock Incentive Plan, which plans to grant 3 million shares of r

### [Keyuan Pharma abandons the acquisition of Hongjitang: Market changes lead to financial mismatch, Linuo Group's 3.58 billion internal asset integration comes to an end | Dayu Finance](https://longbridge.com/en/news/268537626.md)
*2025-12-04T05:46:07.000Z*
> Keyuan Pharma announced the termination of its major asset restructuring to acquire 99.42% equity of Hongjitang for 3.58

### [The 3.5 billion acquisition of Hongjitang has "failed," will the capitalization of traditional Chinese medicine change?](https://longbridge.com/en/news/268156298.md)
*2025-12-02T00:05:19.000Z*
> Keyuan Pharma announced the termination of the major asset restructuring matter to acquire 99.42% equity of Hongjitang,